Precigen, Inc.
PGEN
Positions held
Your positionsPGEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Precigen, Inc. is positioned in the rapidly growing biotechnology sector, focusing on innovative therapies that address unmet medical needs.
- Revenue increased by 136% compared to the prior quarter, reaching $55 million.
- The gross margin improved to 94.9%, up from 89% in the previous quarter.
- The company has a high debt-to-equity ratio of 225.69, indicating significant leverage which could pose risks.
- Precigen reported a net income loss of $7.93 million in Q1 2026, continuing a trend of negative earnings.
- The operating margin was negative at -25.78% in Q1 2026, reflecting ongoing operational challenges.
Fundamentals
| Market cap | $2.72B | Enterprise value | $2.78B | Trailing P/E | — | Forward P/E | -34.55 |
| PEG | — | Price / book | 62.30 | Beta | 0.92 | Dividend yield | 0.00% |
| Revenue growth | 63.2% | Earnings growth | — | Gross margin | 53.0% | Operating margin | 41.2% |
| Profit margin | -1.8% | ROE | -8.4% | ROA | -18.1% | Debt / equity | 2.26 |
| Current ratio | 4.58 | Free cash flow | -$100.10M | Analyst recommendation | buy | Mean target | $13.65 |
| 52w high | $8.98 | 52w low | $2.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $55.0M | $23.3M | $4.6M | $2.9M | $0.9M | — |
| Op margin | 41.2% | -25.8% | -474.6% | -1180.0% | -3254.3% | — |
| Net income | $20.1M | -$7.9M | -$23.5M | -$146M | -$26.6M | — |
| Gross margin | 94.9% | 89.0% | 65.0% | 64.6% | -27.6% | — |
| Gross profit | $52.2M | $20.7M | $3.0M | $1.9M | -$0.2M | — |
| Operating income | $22.6M | -$6.0M | -$21.7M | -$34.5M | -$27.9M | — |
- Revenue +136% vs prior quarter ($55M vs $23M).
- Gross margin 94.9% (was 89% prior quarter).
- Operating margin expanded to 41.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | — |
| Op margin | -1100.8% | -2412.9% | -1428.5% | -277.3% | — |
| Net income | -$251M | -$126M | -$95.9M | $28.3M | — |
| Gross margin | 50.2% | -8.7% | 1.7% | 76.4% | — |
| Gross profit | $4.9M | -$0.3M | $0.1M | $20.6M | — |
| Operating income | -$107M | -$94.7M | -$88.9M | -$74.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
2026-10-05 · Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
2026-10-05 · PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
2026-10-05 · Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
2026-10-05 · The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
2026-10-05 · Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
2026-10-02 · 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
2026-10-01 · UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
2026-10-01 · Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
2026-09-30 · NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
2026-09-30 · uniQure Plunges on Additional Data From Huntington's Disease Study
2026-09-30 · PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Price (daily)
Full chart · RSI · MACD · patterns